345 active
/
1007 total (since 2015)
59
Phase 1 Active
218 total
174
Phase 2 Active
434 total
72
Phase 3 Active
245 total
72
Phase 4 Active
209 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Neurocrine Biosciences 6 5 0
Johnson & Johnson 4 26 5
Neumora Therapeutics, Inc. 3 2 0
COMPASS Pathways 3 2 0
Cybin IRL Limited 3 1 0
Xenon Pharmaceuticals Inc. 3 1 0
AbbVie 2 6 1
Luye Pharma Group Ltd. 2 7 0
Syndeio Biosciences, Inc 2 3 1
Sirtsei Pharmaceuticals, Inc. 2 1 0
Soterix Medical 2 1 0
Enalare Therapeutics Inc. 2 0 0
Seaport Therapeutics 2 0 0
Chengdu Kanghong Pharmaceutical Group Co., Ltd. 2 0 0
Alto Neuroscience 1 6 2
NCT06793397 RECRUITING
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited n=330
NCT06941844 ACTIVE NOT RECRUITING
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Definium Therapeutics US, Inc. n=149
NCT06830044 RECRUITING
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals n=500
NCT04041479 RECRUITING
Biomarker-guided rTMS for Treatment Resistant Depression
Weill Medical College of Cornell University n=348
NCT07263022 NOT YET RECRUITING
Cognitive Strategies in Early Psychosis 2
University of Minnesota n=24
NCT06713616 RECRUITING
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
Yale University n=400
NCT07412756 NOT YET RECRUITING
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company n=1,000
NCT06559306 RECRUITING
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC n=752
NCT07227454 RECRUITING
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC n=258
NCT06564818 RECRUITING
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Cybin IRL Limited n=220
NCT07204314 RECRUITING
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Takeda n=180
NCT06029439 RECRUITING
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Neumora Therapeutics, Inc. n=1,000
NCT06058039 RECRUITING
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Neumora Therapeutics, Inc. n=332
NCT06058013 RECRUITING
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Neumora Therapeutics, Inc. n=332
NCT04777357 RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie n=380
NCT06922110 ENROLLING BY INVITATION
An Open-Label Study of Azetukalner in Major Depressive Disorder
Xenon Pharmaceuticals Inc. n=460
NCT05603104 RECRUITING
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Dr. Inge Winter n=1,254
NCT07196501 RECRUITING
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=550
NCT05711940 ACTIVE NOT RECRUITING
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
COMPASS Pathways n=572
NCT04877197 RECRUITING
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
VA Office of Research and Development n=132
NCT06963021 RECRUITING
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=200
NCT05552053 RECRUITING
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
Cedars-Sinai Medical Center n=150
NCT05624268 ACTIVE NOT RECRUITING
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
COMPASS Pathways n=255
NCT06308653 ACTIVE NOT RECRUITING
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute n=240
NCT07262008 NOT YET RECRUITING
Sustained Mood Improvement With Laughing Gas Exposure
Women's College Hospital n=120
NCT07076407 RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Xenon Pharmaceuticals Inc. n=450
NCT06781697 NOT YET RECRUITING
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
Sunnybrook Health Sciences Centre n=31
NCT06911112 RECRUITING
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=200
NCT06605105 RECRUITING
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Cybin IRL Limited n=468
NCT07227103 NOT YET RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression
NeuroRx, Inc. n=120
NCT07226232 NOT YET RECRUITING
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
VA Office of Research and Development n=240
NCT05474846 RECRUITING
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
M.D. Anderson Cancer Center n=188
NCT05944926 RECRUITING
Improving Outcomes in Depression in Primary Care in a Low Resource Setting
Harvard Medical School (HMS and HSDM) n=1,500
NCT06786624 RECRUITING
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=200
NCT05625360 RECRUITING
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
Wake Forest University Health Sciences n=160
NCT06273527 RECRUITING
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
University of California, San Diego n=128
NCT06775379 RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Xenon Pharmaceuticals Inc. n=450
NCT05415397 RECRUITING
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
Amsterdam UMC, location VUmc n=140
NCT05973851 RECRUITING
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Dr. Inge Winter n=418
NCT06765057 RECRUITING
Effect of Probiotics "Psychobiotics" on Depression and Metabolic Syndrome in Saudi Arabia
Roaa Ahmed Alkreadees n=60
NCT06529029 RECRUITING
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Michigan State University n=30
NCT07153406 NOT YET RECRUITING
Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla n=220
NCT06943573 NOT YET RECRUITING
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
Lakshmi N Yatham n=90
NCT06698666 RECRUITING
Efficacy of Statins Among Major Depressive Disorder
Ain Shams University n=145
NCT07120880 NOT YET RECRUITING
Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia
Assistance Publique - Hôpitaux de Paris n=184
NCT06303739 RECRUITING
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
University of North Carolina, Chapel Hill n=23
NCT05186272 ACTIVE NOT RECRUITING
mHealth Mindfulness Intervention for Pregnant Black and Latina Women at Risk of Postpartum Depression
Kaiser Permanente n=600
NCT06966401 RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=600
NCT07088380 RECRUITING
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Università Vita-Salute San Raffaele n=30
NCT07084454 ENROLLING BY INVITATION
Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care
Cristiane Decat Bergerot, PhD n=350
NCT05850689 RECRUITING
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=470
NCT06247839 RECRUITING
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sharmin Ghaznavi n=20
NCT06958692 RECRUITING
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
CSPC Ouyi Pharmaceutical Co., Ltd. n=388
NCT06957704 NOT YET RECRUITING
Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents
Federal University of São Paulo n=60
NCT03167905 ACTIVE NOT RECRUITING
CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery)
KK Women's and Children's Hospital n=881
NCT06891300 RECRUITING
Understanding and Treating Suicidal Ideation With Ketamine
The Royal's Institute of Mental Health Research n=36
NCT05518149 ACTIVE NOT RECRUITING
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Janssen Research & Development, LLC n=840
NCT06860958 RECRUITING
Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Tanta University n=60
NCT04116528 ACTIVE NOT RECRUITING
Opiate Suicide Study in Patients With Major Depression
Stanford University n=60
NCT06827431 NOT YET RECRUITING
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=770
NCT06765824 NOT YET RECRUITING
Transcranial Magnetic Stimulation in Patients with Dual Disorders
Cardenal Herrera University n=36
NCT06752759 RECRUITING
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
Theresa Jacob, PhD, MPH n=40
NCT05644301 RECRUITING
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
Universiteit Antwerpen n=240
NCT04011163 ACTIVE NOT RECRUITING
Vital Signs-Integrated Patient-Assisted Intravenous Opioid Analgesia for Post Surgical Pain
KK Women's and Children's Hospital n=40
NCT06590025 RECRUITING
Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for Depression
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=296
NCT06074250 RECRUITING
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
The Canadian College of Naturopathic Medicine n=100
NCT03423680 RECRUITING
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Korea Otsuka Pharmaceutical Co., Ltd. n=390
NCT03684447 ACTIVE NOT RECRUITING
Neural and Antidepressant Effects of Propofol
University of Utah n=48
NCT02568878 RECRUITING
Creatine for Depressed Male and Female Methamphetamine Users
Montana State University n=29
NCT06979544 COMPLETED
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Lipocine Inc. n=90
NCT06514742 TERMINATED
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
Janssen Research & Development, LLC n=101
NCT06635135 TERMINATED
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
Janssen Research & Development, LLC n=48
NCT05550532 COMPLETED
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Janssen Research & Development, LLC n=444
NCT05233566 COMPLETED
Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
Washington University School of Medicine n=32
NCT06360419 COMPLETED
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Axsome Therapeutics, Inc. n=346
NCT02783430 COMPLETED
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
University Hospital, Lille n=42
NCT07253207 COMPLETED
Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder
Zhejiang Huahai Pharmaceutical Co., Ltd. n=392
NCT04592809 COMPLETED
Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
University of Texas Southwestern Medical Center n=50
NCT06029426 COMPLETED
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Neumora Therapeutics, Inc. n=383
NCT06011577 TERMINATED
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
Levomecor Inc. n=27
NCT04855747 TERMINATED
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Levomecor Inc. n=236
NCT05455684 COMPLETED
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Janssen Research & Development, LLC n=513
NCT03421808 COMPLETED
EEG Synchronized TMS Trial for Depression
Medical University of South Carolina n=34
NCT05061719 COMPLETED
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=812
NCT06048263 WITHDRAWN
The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series
Washington University School of Medicine
NCT02942004 COMPLETED
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
Supernus Pharmaceuticals, Inc. n=138
NCT03665038 COMPLETED
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Supernus Pharmaceuticals, Inc. n=28
NCT02942017 COMPLETED
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
Supernus Pharmaceuticals, Inc. n=108
NCT04513912 COMPLETED
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Janssen Research & Development, LLC n=757
NCT03053362 COMPLETED
THINC-it Vortioxetine - Sensitivity to Change
Brain and Cognition Discovery Foundation n=158
NCT04532749 TERMINATED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Janssen Research & Development, LLC n=212
NCT03231358 COMPLETED
Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa
Brown University n=1,758
NCT04260607 TERMINATED
Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department
Naval Medical Center Camp Lejeune n=1
NCT04973930 SUSPENDED
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
New York State Psychiatric Institute n=20
NCT05061706 COMPLETED
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=480
NCT04985942 COMPLETED
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=485
NCT05391555 COMPLETED
Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
University of California, San Francisco n=10
NCT02782104 COMPLETED
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Janssen Research & Development, LLC n=1,148
NCT02418585 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=236
NCT04338321 COMPLETED
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
Janssen-Cilag International NV n=676
NCT03434041 COMPLETED
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=252
NCT03097133 COMPLETED
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Janssen Research & Development, LLC n=230
NCT02493868 COMPLETED
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=719
NCT03039192 COMPLETED
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Janssen Research & Development, LLC n=226
NCT02422186 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=139
NCT02417064 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=346
NCT02497287 COMPLETED
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Janssen Research & Development, LLC n=802
NCT04533529 COMPLETED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
Janssen Research & Development, LLC n=588
NCT03852160 WITHDRAWN
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Janssen-Cilag International NV
NCT03693105 TERMINATED
The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition
Magnus Medical n=2
NCT04285515 COMPLETED
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=488
NCT05227209 TERMINATED
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
Sumitomo Pharma America, Inc. n=64
NCT04939649 COMPLETED
Ketamine As an Adjunctive Therapy for Major Depression (2)
University of Dublin, Trinity College n=63
NCT04855760 COMPLETED
Safety of REL-1017 for Major Depressive Disorder
Relmada Therapeutics, Inc. n=627
NCT06735079 WITHDRAWN
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)
MGGM LLC
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT03947827 COMPLETED
Minocycline As Adjunctive Treatment for Treatment Resistant Depression
Centre for Addiction and Mental Health n=76
NCT06717724 COMPLETED
§ Procaine Periarticular Injections for Pain Reduction in Elderly With Osteoarthritis
Sf Luca Chronic Disease Hospital n=203
NCT04504253 COMPLETED
A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
University of Utah n=18
NCT05169710 TERMINATED
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
Sumitomo Pharma America, Inc. n=83
NCT03864614 COMPLETED
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
Biogen n=1,515
NCT04688164 COMPLETED
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Relmada Therapeutics, Inc. n=227
NCT03697603 COMPLETED
A Study of Brexpiprazole in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd. n=740
NCT03909217 COMPLETED
Treating Depression With Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS).
The University of Hong Kong n=470
NCT03737474 COMPLETED
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd. n=248
NCT01928446 TERMINATED
Lithium for Suicidal Behavior in Mood Disorders
VA Office of Research and Development n=519
NCT05081167 COMPLETED
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Relmada Therapeutics, Inc. n=232
NCT04345471 COMPLETED
A Study of MD-120 in Patients With Depression
Mochida Pharmaceutical Company, Ltd. n=615
NCT04442490 COMPLETED
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
Biogen n=543
NCT04476030 COMPLETED
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
Biogen n=440
NCT02978326 COMPLETED
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
Biogen n=276
NCT04442503 COMPLETED
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
Biogen n=200
NCT03771664 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
Biogen n=87
NCT03672175 COMPLETED
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder
Biogen n=581
NCT04007367 TERMINATED
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
Biogen n=53
NCT04603781 SUSPENDED
CBD Oil for Reducing Emotional Impact of COVID-19
University of Texas at Austin n=200
NCT05427981 WITHDRAWN
Anti-suicidal Effects of Buprenorphine In Depressed Individuals
New York State Psychiatric Institute
NCT03538691 COMPLETED
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,149
NCT03113968 COMPLETED
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Bo Hu n=403
NCT03573297 COMPLETED
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
AbbVie n=901
NCT04476446 COMPLETED
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
Janssen-Cilag, S.A. n=41
NCT03674671 SUSPENDED
Ketamine Versus Electroconvulsive Therapy in Depression
University of Ottawa n=240
NCT05950061 COMPLETED
Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder
KRL Hospital, Islamabad n=744
NCT03485274 COMPLETED
Substance Misuse To Psychiatric Disorders for Cannabis
The University of Hong Kong n=37
NCT05482672 WITHDRAWN
GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression
Cale Andrew Jacobs, PhD
NCT03889756 TERMINATED
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
Yale University n=3
NCT03105245 COMPLETED
Understanding How Anaesthesia Affects ECT Outcomes
The University of New South Wales n=54
NCT04162522 COMPLETED
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
University Health Network, Toronto n=1
NCT03539887 COMPLETED
Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
The University of Texas Health Science Center, Houston n=33
NCT04227704 COMPLETED
Ketamine to Prevent PPD After Cesarean
Washington University School of Medicine n=25
NCT04383691 TERMINATED
A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression
Sumitomo Pharma (Suzhou) Co., Ltd. n=124
NCT05014919 TERMINATED
Vortioxetine to Prevent Return of Symptoms in Children With Depression
H. Lundbeck A/S n=35
NCT02871297 TERMINATED
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
H. Lundbeck A/S n=662
NCT02674529 COMPLETED
Study of Neural Responses Induced by Antidepressant Effects
Marta Peciña, MD PhD n=60
NCT03738215 COMPLETED
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
AbbVie n=759
NCT04019704 COMPLETED
A Trial of AXS-05 in Patients With Major Depressive Disorder
Axsome Therapeutics, Inc. n=327
NCT04039022 COMPLETED
Open-Label Safety Study of AXS-05 in Subjects With Depression
Axsome Therapeutics, Inc. n=876
NCT02709655 COMPLETED
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
H. Lundbeck A/S n=683
NCT03739203 COMPLETED
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
AbbVie n=752
NCT04832425 COMPLETED
A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
Praxis Precision Medicines n=216
NCT02532660 TERMINATED
Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode
Laboratório Catarinense SA n=111
NCT02553915 COMPLETED
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
Massachusetts General Hospital n=61
NCT04000009 TERMINATED
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
ACADIA Pharmaceuticals Inc. n=235
NCT02624102 COMPLETED
Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression
Hemanny, Curt, M.D. n=76
NCT03569475 COMPLETED
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
Allergan n=501
NCT04405791 COMPLETED
Efficacy of Clinical Application of Transcranial Low Intensity Focused Ultrasonic Stimulation for Patients With Major Deperessive Disorder - Exploratory Clinical Trial
Gangnam Severance Hospital n=30
NCT02726659 TERMINATED
Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=1
NCT02556606 COMPLETED
Ketamine for Treatment Resistant Late-Life Depression
VA Office of Research and Development n=33
NCT04364997 COMPLETED
Study of Desvenlafaxine in Treating Major Depressive Disorder.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=420
NCT03968159 COMPLETED
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
ACADIA Pharmaceuticals Inc. n=298
NCT04853407 COMPLETED
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
Luye Pharma Group Ltd. n=558
NCT03435744 COMPLETED
Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.
Pakistan Institute of Living and Learning n=150
NCT02987985 COMPLETED
Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy
University of Saskatchewan n=50
NCT03610048 TERMINATED
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
Alkermes, Inc. n=175
NCT03108625 COMPLETED
Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
H. Lundbeck A/S n=94
NCT03395353 TERMINATED
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Shionogi n=151
NCT03026426 COMPLETED
Effectiveness of a mHealth Intervention for the Treatment of Depression in People With Diabetes or Hypertension in Peru
Universidad Peruana Cayetano Heredia n=432
NCT03188185 COMPLETED
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
Alkermes, Inc. n=278
NCT02389816 COMPLETED
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
Takeda n=493
NCT02741791 COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
Axsome Therapeutics, Inc. n=312
NCT03652948 COMPLETED
Meru Health Ascend Mobile Intervention for Depression in Middle Aged and Older Adults
Palo Alto Veterans Institute for Research n=70
NCT02535572 COMPLETED
Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment
Medical University of South Carolina n=48
NCT04091139 COMPLETED
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
Chinese University of Hong Kong n=27
NCT04216888 COMPLETED
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
Dan Iosifescu n=9
NCT03315793 COMPLETED
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
Shionogi n=149
NCT03487198 TERMINATED
The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
Otsuka Beijing Research Institute n=65
NCT03614156 TERMINATED
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc n=363
NCT04393818 COMPLETED
Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19
Fundació d'investigació Sanitària de les Illes Balears n=560
NCT02686333 COMPLETED
Meditation for Depression and Anxiety Symptoms in Dialysis Patients
Lady Davis Institute n=50
NCT02431806 COMPLETED
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
Forest Laboratories n=552
NCT03560518 TERMINATED
Study of Rapastinel as Monotherapy in Patients With MDD
Naurex, Inc, an affiliate of Allergan plc n=439
NCT02709746 COMPLETED
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
H. Lundbeck A/S n=784
NCT02988076 SUSPENDED
Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression
MYnd Analytics n=468
NCT03675776 TERMINATED
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc n=50
NCT03668600 TERMINATED
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc n=230
NCT03002077 COMPLETED
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
Naurex, Inc, an affiliate of Allergan plc n=617
NCT02951988 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
Naurex, Inc, an affiliate of Allergan plc n=1,304
NCT02191397 COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
GlaxoSmithKline n=534
NCT03436121 WITHDRAWN
Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department
Maria Pacella
NCT02943564 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
Naurex, Inc, an affiliate of Allergan plc n=658
NCT02659085 COMPLETED
Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder
Pouya Movahed Rad n=198
NCT02943577 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
Naurex, Inc, an affiliate of Allergan plc n=429
NCT02932943 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
Naurex, Inc, an affiliate of Allergan plc n=465
NCT02372799 COMPLETED
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
Forest Laboratories n=473
NCT02436239 COMPLETED
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
Forest Laboratories n=330
NCT02418702 WITHDRAWN
A Study to Decrease Suicidal Thinking Using Ketamine
United States Naval Medical Center, San Diego
NCT02720198 COMPLETED
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
Duke University n=60
NCT02703363 COMPLETED
Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression
Pakistan Institute of Living and Learning n=265
NCT02358343 COMPLETED
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
University of Washington n=184
NCT03855865 WITHDRAWN
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc
NCT02838043 COMPLETED
The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients
Queen's University n=10
NCT02466087 COMPLETED
Role of Magnesium Supplementation in the Treatment of Depression
University of Vermont n=126
NCT02583867 COMPLETED
Predictors of Depression Treatment Response to Exercise
University of Texas Southwestern Medical Center n=38
NCT02670538 COMPLETED
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
Forest Laboratories n=493
NCT02670551 COMPLETED
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
Forest Laboratories n=488
NCT02451293 COMPLETED
The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome
Zealand University Hospital n=252
NCT02846662 COMPLETED
Effectiveness of a Mobile Technology Intervention for the Treatment of Depression
University of Sao Paulo General Hospital n=880
NCT02367521 COMPLETED
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)
Johns Hopkins University n=70
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT02507219 COMPLETED
Study of Ibuprofen Effects on Brain Function
Laureate Institute for Brain Research, Inc. n=24
NCT02308956 COMPLETED
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
University of Cape Town n=324
NCT02400346 COMPLETED
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
H. Lundbeck A/S n=132
NCT02657980 COMPLETED
The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder
Ybrain Inc. n=96
NCT02845349 WITHDRAWN
Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)
Johns Hopkins University
NCT02423824 COMPLETED
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
University Health Network, Toronto n=21
NCT02443194 TERMINATED
The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
michal roll n=50
Data: ClinicalTrials.gov